tradingkey.logo
搜索

Evolus Inc

EOLS
添加自选
6.900USD
+0.160+2.37%
收盘 07/02, 13:00美东报价延迟15分钟
454.29M总市值
亏损市盈率 TTM

关于 Evolus Inc 公司

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc简介

公司代码EOLS
公司名称Evolus Inc
上市日期Feb 08, 2018
CEOMoatazedi (David)
员工数量332
证券类型Ordinary Share
年结日Feb 08
公司地址520 Newport Center Dr Ste 1200
城市NEWPORT BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92660-7022
电话19492844555
网址https://www.evolus.com/
公司代码EOLS
上市日期Feb 08, 2018
CEOMoatazedi (David)

Evolus Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

常见问题

Evolus Inc的前五大股东是谁?

Evolus Inc 的前五大股东如下:Mr. Vikram Malik

有多少机构持有Evolus Inc(EOLS)的股份?

截至2026Q1,共有391家机构持有Evolus Inc的股份,合计持有的股份价值约为50.03M,占公司总股份的75.98%。与2025Q4相比,机构持股有所增加,增幅为-16021350.00。